VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01

Trial Profile

VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2017

At a glance

  • Drugs VXM-01 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors VAXIMM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Apr 2017 Planned number of patients changed from 24 to 6.
    • 28 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top